Agios Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Agios Pharmaceuticals, Inc. carries a market capitalization of 2.10B, placing it among publicly traded companies globally. Its enterprise value stands at 1.63B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.10B |
| Enterprise Value | 1.63B |
Share Statistics
Agios Pharmaceuticals, Inc. currently has 59.60M shares outstanding.
| Shares Outstanding | 59.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 22.19, and the price-to-book ratio stands at 2.16.
| PE Ratio | N/A |
| PS Ratio | 22.19 |
| PB Ratio | 2.16 |
| P/TBV Ratio | 2.16 |
| P/FCF Ratio | -6.13 |
| P/OCF Ratio | -6.05 |
Enterprise Valuation
| EV / Sales | 16.53 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Agios Pharmaceuticals, Inc. maintains a current ratio of 10.22, meaning it holds 10.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.22 |
| Quick Ratio | 9.14 |
| Debt / Equity | 3.04 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -34.34 |
| Return on Assets (ROA) | -31.89 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.26 |
Taxes
| Income Tax | -1.02M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Agios Pharmaceuticals, Inc.'s stock has declined approximately -17.63564% over the past 52 weeks. The 50-day moving average sits at 33.11, while the 200-day moving average is 31.31.
| Beta (5Y) | N/A |
| 52-Week Price Change | -17.63564% |
| 50-Day Moving Average | 33.11 |
| 200-Day Moving Average | 31.31 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Agios Pharmaceuticals, Inc. generated 98.34M in revenue and converted that into -411.29M in net income, yielding earnings per share of -6.99. EBITDA reached -453.67M, while operating income came in at -459.02M.
| Revenue | 98.34M |
| Gross Profit | 90.47M |
| Operating Income | -459.02M |
| Pretax Income | -412.30M |
| Net Income | -411.29M |
| EBITDA | -453.67M |
| EBIT | -459.02M |
| Earnings Per Share (EPS) | -6.99 |
Balance Sheet
Agios Pharmaceuticals, Inc. holds 617.58M in cash and equivalents against 31.17M in total debt, resulting in a net debt position of -99.65M. Total book value stands at 1.03B, with working capital of 647.45M providing operational flexibility.
| Cash & Cash Equivalents | 617.58M |
| Total Debt | 31.17M |
| Net Debt | -99.65M |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 17.21 |
| Working Capital | 647.45M |
Cash Flow
Agios Pharmaceuticals, Inc. produced -360.60M in operating cash flow over the past twelve months. After subtracting -4.66M in capital expenditures, free cash flow totaled -365.25M - equivalent to -6.21 per share.
| Operating Cash Flow | -360.60M |
| Capital Expenditures | -4.66M |
| Free Cash Flow | -365.25M |
| FCF Per Share | -6.21 |
Margins
Agios Pharmaceuticals, Inc. operates with a gross margin of 91.99, reflecting its pricing power and cost economics. The operating margin of -466.78 and net profit margin of -418.24 provide insight into operational efficiency.
| Gross Margin | 91.99 |
| Operating Margin | -466.78 |
| Pretax Margin | -419.27 |
| Profit Margin | -418.24 |
| EBITDA Margin | -461.34 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.55 |
| FCF Yield | -16.31 |
Scores
Agios Pharmaceuticals, Inc. posts an Altman Z-Score of 14.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 14.57 |